Expert Discusses Practice-Changing Data From KATHERINE Trial in Breast Cancer
Mark D. Pegram, MD, discusses how the results from the phase III KATHERINE trial will change practice for the treatment of patients with breast cancer.
Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses how the results from the phase III KATHERINE trial will change practice for the treatment of patients with breast cancer.
To date, Pegram says that physicians have had the option of using a second antibody in high-risk patients with early-stage disease. Now there is biological evidence to using these agents in the neoadjuvant setting and treatments can be tailored more based on their pathologic complete response, or lack thereof, says Pegram.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
